• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog » Prescribing Newer Antidepressants

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

Prescribing Newer Antidepressants

May 3, 2019
Michael Gitlin, MD, director of the Outpatient Mood Disorder Program at UCLA gave The Carlat Psychiatry Report his view on newer antidepressants. He emphasized that these newer medications are no more effective than our standard antidepressants, but that it’s always good to have more options available for patients who may not have responded to—or who can’t tolerate—other medication trials. Here are some of Dr. Gitlin’s impressions about the newer antidepressants.

Vilazodone (Viibryd)
“It has serotonin transporter blocking properties like an SSRI, and it seems to affect the serotonin A1 receptor like buspirone. But while it has been shown to help for comorbid anxiety and for generalized anxiety disorder when compared to placebo, there isn’t any data to show it’s any better than SSRIs for these conditions.

Be aware that vilazodone can be overly stimulating, which might not be something you want for a patient with comorbid anxiety. To minimize that kind of side effect, have the patient take it in the morning. Also let patients know that the rate of stimulation diminishes over a period of weeks.

Use the dosing that the manufacturers recommend: Start at 10 mg, then 20 mg, and then up to 40. Be aware, though, that dosing at 40 can cause nausea or added stimulation. The vilazodone package insert says that absorption is improved if you take vilazodone with food.”

Vortioxetine (Trintellix)
“Like vilazodone, vortioxetine has clear SSRI-like properties: It blocks the presynaptic serotonin transporter, but unlike vilazodone, it also prominently affects many of the serotonin subreceptors. Let patients know that GI side effects can include nausea, vomiting, diarrhea, and constipation.
As for dosing, start at 5 mg, go up to 10, and don’t exceed a full dose of 20 mg. At 20 mg, side effects can become an issue.”

Levomilnacipran (Fetzima)
“Levomilnacipran is an isomer of milnacipran, which is marketed as Savella, a drug FDA indicated for fibromyalgia. But milnacipran has close to a dozen controlled studies showing that it’s an effective antidepressant. It is an SNRI, a dual action agent, so you can compare it with other SNRIs, including venlafaxine, desvenlafaxine, and duloxetine. As for implications of levomilnacipran’s noradrenergic prominence? It doesn’t affect its efficacy, but rather its side effect profile. Tell patients that side effects include constipation and sweating.”

Registered users and subscribers can read the full interview with Dr. Gitlin, including his take on the role of antipsychotics for treating depression. Become a subscriber today, or register for free here.
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.